The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

clingenuity.com

Stage

Acquired | Acquired

About ClinGenuity

ClinGenuity offers clients research and development services to the pharmaceutical and medical device industries. The company uses its patent-pending artificial intelligence and expert team of medical writers to increase new drug and medical device development efficiencies, thereby reducing development cycle times.

ClinGenuity Headquarter Location

9435 Waterstone Boulevard Suite 100

Cincinnati, Ohio, 45249,

United States

513-239-6918

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ClinGenuity

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ClinGenuity is included in 1 Expert Collection, including Artificial Intelligence.

A

Artificial Intelligence

8,694 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

ClinGenuity Patents

ClinGenuity has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/24/2012

9/5/2017

Clinical research, Clinical trials, Clinical data management, Data management, Pharmaceutical industry

Grant

Application Date

10/24/2012

Grant Date

9/5/2017

Title

Related Topics

Clinical research, Clinical trials, Clinical data management, Data management, Pharmaceutical industry

Status

Grant

Latest ClinGenuity News

Certaras ClinGenuity Named a Cool Vendor in Gartners 2015 Life Sciences Report

Apr 30, 2015

Pharma contributes £32 billion to UK economy “We are delighted that Gartner has recognized us,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “ClinGenuity’s artificial intelligence (AI)-assisted clinical trial writing tools can serve to shorten the new drug application process, helping to bring new therapies to patients faster.” Synchrogenix, powered by ClinGenuity, uses an AI/natural language recognition and processing engine to identify individual words, parts of speech, word combinations, phrases and phrasing combinations. The system is intelligent enough to analyze previously written documents in order to construct an automated process for developing new clinical study documents and redacting information based on pre-defined process rules. With extremely high accuracy and efficiency, this configurable technology-enabled solution is unmatched in the industry. “With the introduction of new clinical trial data disclosure regulations, including European Medicines Agency Policy 70, which went into effect at the start of 2015, we are seeing increased demand for our AI-based ClinGenuity Redaction Management System which efficiently removes all the personal patient and company confidential information from reports with 99 percent accuracy, prior to release,” said Keith Kleeman, Synchrogenix president and ClinGenuity founder. “We are working with a growing number of biopharmaceutical companies that are seeking strategic partners to support their global filings. The ClinGenuity technology strengthens our work with those companies.” One of the four key findings in Gartner’s report was that process optimization in clinical trial startup and writing can have a demonstrable and significant impact on cycle times and the acceleration of deliverables. This Gartner research report1 focuses on maximizing revenue, improving research efforts, building deep customer relationships through advanced analytics, and optimizing clinical cycle times by improving study startup and clinical writing. Disclaimer Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. 1 Gartner “Cool Vendors in Life Sciences, 2015” by Stephen Davies and Michael Shanler, 13 April 2015. About Synchrogenix, Powered by ClinGenuity, a Certara™ Company Synchrogenix, Powered by ClinGenuity, a Certara company, encompasses a group of separate entities operating together to provide regulatory and medical writing services to the pharmaceutical, biotech, and medical device industry worldwide. Synchrogenix Information Strategies Inc.; Synchrogenix Europe, Ltd.; and Synchrogenix Philippines, Inc. (SPI) are all wholly owned subsidiaries with an overall governance structure that creates and enforces a global standard of service, technology, and quality. About Certara Certara is a global biosimulation technology-enabled drug development consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit  www.certara.com . Certara Contact:

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.